Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease. - Wikidata - wikimedia - TriplyDB

Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease.

Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease.

http://www.wikidata.org/entity/Q45939318

about

The Gut Microbiota in Immune-Mediated Inflammatory Diseases Potential Benefits of Dietary Fibre Intervention in Inflammatory Bowel Disease Modulating Composition and Metabolic Activity of the Gut Microbiota in IBD Patients Microbiota Manipulation With Prebiotics and Probiotics in Patients Undergoing Stem Cell Transplantation The gut microbiota and host health: a new clinical frontier The Intestinal Microbiota in Inflammatory Bowel Disease Gut microbial flora, prebiotics, and probiotics in IBD: their current usage and utility The role of probiotic lactic acid bacteria and bifidobacteria in the prevention and treatment of inflammatory bowel disease and other related diseases: a systematic review of randomized human clinical trials Probiotics, prebiotics and immunomodulation of gut mucosal defences: homeostasis and immunopathology Chemically defined diet alters the protective properties of fructo-oligosaccharides and isomalto-oligosaccharides in HLA-B27 transgenic rats Modulation of microbiota as treatment for intestinal inflammatory disorders: An uptodate Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease Diet, gut microbes, and the pathogenesis of inflammatory bowel diseases.A high-fiber diet may improve bowel function and health-related quality of life in patients with Crohn disease Dietary fiber information for individuals with Crohn disease: reports of gastrointestinal effects.Fermentable carbohydrates (FODMAPs) exacerbate functional gastrointestinal symptoms in patients with inflammatory bowel disease: a randomised, double-blind, placebo-controlled, cross-over, re-challenge trial.Potential role of nutraceutical compounds in inflammatory bowel disease The microbiota in inflammatory bowel disease: current and therapeutic insights Exploring the influence of the gut microbiota and probiotics on health: a symposium report.Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years?The effect of selected synbiotics on microbial composition and short-chain fatty acid production in a model system of the human colon.Review article: dietary fibre-microbiota interactions.Review article: evidence-based dietary advice for patients with inflammatory bowel disease.Mechanisms and effectiveness of prebiotics in modifying the gastrointestinal microbiota for the management of digestive disorders.Association of gut microbiota with post-operative clinical course in Crohn's disease.Nutrigenetics, nutrigenomics and inflammatory bowel diseases.Role of the enteric microbiota in intestinal homeostasis and inflammation British Dietetic Association evidence-based guidelines for the dietary management of Crohn's disease in adults.Modulating the microbiota in inflammatory bowel diseases: prebiotics, probiotics or faecal transplantation?Intestinal microbiota, probiotics and prebiotics in inflammatory bowel disease.The microbiome in inflammatory bowel disease and its modulation as a therapeutic manoeuvre.Diet in the pathogenesis and treatment of inflammatory bowel diseases Can inflammatory bowel disease be permanently treated with short-term interventions on the microbiome?Fructooligosaccharides exert intestinal anti-inflammatory activity in the CD4+ CD62L+ T cell transfer model of colitis in C57BL/6J mice.Microbiota in Inflammatory Bowel Disease Pathogenesis and Therapy: Is It All About Diet?Characterisation and therapeutic manipulation of the gut microbiome in inflammatory bowel disease.Fecal Microbiota Transplantation as a Novel Therapy for Ulcerative Colitis: A Systematic Review and Meta-Analysis IBS and IBD - separate entities or on a spectrum?Specific immunotherapy in combination with Clostridium butyricum inhibits allergic inflammation in the mouse intestine.Metabolic profiling of the impact of oligofructose-enriched inulin in Crohn's disease patients: a double-blinded randomized controlled trial.

P2860

Q26741414-9D6F83A0-4E00-40E2-8775-DA47723507DE Q26744514-2E4CB829-D188-48A0-86B3-F4481B095727 Q26750985-71F47ED2-0199-4DA8-993D-A7BB3A7758A4 Q26771287-8A2B461B-85B0-438F-8B11-D849148FD766 Q26785649-195D37E0-068C-4A2B-93E2-21210D25B0AA Q26795705-8BABD62E-067B-4637-93F9-E32D59A0F1BB Q26995672-C585987F-3AD7-4E8C-95D9-96F60C50C3CD Q27001546-80D0A18A-112D-4785-B609-837D82E6E172 Q27027791-3B41C249-5F30-4BA5-BD7A-3495B08A477C Q27332418-01A201CC-F79E-4FB6-BC01-09427ABD629B Q28072437-D6B5C670-9927-4640-A65F-540F2522FE4C Q28254207-8257B5FA-FC0E-40B1-B244-3C49AC5202BC Q30249313-E5C5FE11-FA60-4791-9484-E142AC0A7750 Q30405495-D796F43D-505E-4781-8EA0-928E14B84A77 Q30410987-D3FB116B-582D-40A4-85B8-949A90AC429D Q33470528-BCCC7E2A-846D-4F6C-A676-C9B182F0CCFD Q33572633-00B12202-ACBB-471F-A2C1-FFAE958CDB71 Q33806817-1C6D0803-E4D1-47A0-BF82-3D279A74DB44 Q33829118-D9B1580B-6B2F-4CF0-B33D-4E5C982664E3 Q34407175-EA8B42CB-3737-47D0-A88A-E747DAD6C835 Q34452017-BA6992DA-F061-46EF-A60D-75FBAADCAD86 Q34477939-20F5D033-B207-450F-83D7-6AD05D5C2BD1 Q34656566-DE77C69D-CE37-4CED-94CF-1722C8ACA80E Q34726491-0135BF82-800F-4710-8DB0-83F19398C4E6 Q34960634-A91D5999-6E6A-467A-9829-3E144EFFA067 Q34967922-A52FEC93-3C04-4E07-905B-060720FE6EE2 Q35052712-C2EACB9C-12C6-4F0A-A7C3-A93FC6212356 Q35061688-C891CA33-FA66-40DC-B4A7-0186EDA5DA4C Q35195891-61CF4244-8B15-4F7D-9DBB-0F2D820DE837 Q35245299-52ABC254-5323-44F9-82B6-DDC0099A8603 Q35252410-4459D2F8-DB72-41F7-AC08-E3B76DB53359 Q35537121-55DA4632-2CA3-49C8-B41D-909D3A35DD6A Q35558415-9873EDE7-F90D-4CB2-817E-D6D8B9AA6E60 Q35686196-EBD99CE9-E4A8-4B0D-86E2-92F44B1BBAED Q35801931-369E366F-00B9-43D1-A8BF-3184468DC9CF Q35954425-E5ABCD5C-377E-4FAF-884D-AEB3FCC903E3 Q36046935-3D99D47E-E679-4D93-9745-9F08412F5674 Q36144375-5B57B5AA-9105-41C9-B222-EDF52692C250 Q36340310-ABA66661-D6D7-41A1-B6F1-0221481726D6 Q36579696-E211176D-68F3-42AE-9FD6-22EBC3F44F09

P2860

Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease.

http://www.wikidata.org/entity/Q45939318

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Randomised, double-blind, plac ...... des in active Crohn's disease.

@en

Randomised, double-blind, plac ...... des in active Crohn's disease.

@nl

type

label

Randomised, double-blind, plac ...... des in active Crohn's disease.

@en

Randomised, double-blind, plac ...... des in active Crohn's disease.

@nl

prefLabel

Randomised, double-blind, plac ...... des in active Crohn's disease.

@en

Randomised, double-blind, plac ...... des in active Crohn's disease.

@nl

P1433

Q45939318-B4AE9BEB-6ECE-4CBB-99B3-6B712558000A

P1476

Q45939318-E9EDCC17-865A-4B1C-9115-52414E6EC3ED

P2093

Q45939318-060274D6-FA5A-40B8-B700-2F4081586018

Q45939318-06C48AEF-360B-480B-A85F-B6B02198C3B5

Q45939318-452CC6D6-D04F-45B2-8F4C-5F07D960830A

Q45939318-5B94FCB4-B589-4821-8440-D3FC90A1FC97

Q45939318-66AC0F64-1451-4195-A40F-4F3E2B50B05B

Q45939318-6FC0241C-3DB8-4890-817E-CCE93370870D

Q45939318-80C7FA2A-8B5F-40FE-B0E4-F517889F36C9

Q45939318-9A0D7CF4-1D6D-4014-95CA-F9D56B209BCC

Q45939318-D4D29F37-4F27-44FD-B308-1E324C2B1D95

Q45939318-FE89FBEC-BD9E-4402-94B8-9F1A108A85D4

P304

Q45939318-099245EC-CFB0-4C0F-B389-FFF4F4035E93

P31

Q45939318-B95652CD-A473-4F66-837C-DA833E8284E0

P356

Q45939318-DCB7E95F-D606-4446-81B0-827539036A02

P407

Q45939318-85BC9A74-5DFD-4E55-958D-E2155DBA8341

P433

Q45939318-2DCE6E93-E0A1-4B9E-ACCC-AF78EA350578

P478

Q45939318-662D47B9-D4BD-4529-B7DE-24E80C3FE785

P50

Q45939318-7E3BBD86-C6FC-45AA-96D3-B64B944FB03E

Q45939318-A9305F47-10B6-460C-9B98-1543F84B3D6A

Q45939318-B61CCACC-9DB5-4EA3-90A0-B4D618CBFAFA

P577

Q45939318-60BBD244-B46E-49CC-95CA-53D27D518556

P698

Q45939318-A09FCAC1-1A27-46A0-9701-4775421D1CFA

P921

Q45939318-67A9BBA7-7065-498D-98EC-122DEC3822CB

Q45939318-AA9B0355-1A6C-40BC-AD08-C6469A8058CB

P356

GUT.2010.232025

P1433

P1476

Randomised, double-blind, plac ...... des in active Crohn's disease.

@en

P2093

Ailsa L Hart

http://www.w3.org/2001/XMLSchema#string

Andreas Koutsoumpas

http://www.w3.org/2001/XMLSchema#string

Andrew J Stagg

http://www.w3.org/2001/XMLSchema#string

Charlotte R H Hedin

http://www.w3.org/2001/XMLSchema#string

James O Lindsay

http://www.w3.org/2001/XMLSchema#string

Jane L Benjamin

http://www.w3.org/2001/XMLSchema#string

Jeremy D Sanderson

http://www.w3.org/2001/XMLSchema#string

Kevin Whelan

http://www.w3.org/2001/XMLSchema#string

Michael A Kamm

http://www.w3.org/2001/XMLSchema#string

Stella C Knight

http://www.w3.org/2001/XMLSchema#string

P304

923-929

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/GUT.2010.232025

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P50

Neil E McCarthy

Alastair Forbes

P577

2011-01-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21262918

http://www.w3.org/2001/XMLSchema#string

P921

oligosaccharide